Allergan to Consolidate European Operations
- Share via
Allergan Inc., the maker of Botox injections to smooth wrinkles, said it would consolidate its European research and development operations to save as much as $9 million a year.
Operations at the plants to be closed will be moved to Britain, Ireland and the U.S., Irvine-based Allergan said. The closings, which also affect some sales operations, will cost the company about $50 million to $60 million through the second quarter of 2006.
Shares of Allergan rose $1.24, or 1.6%, to $81.02 on the NYSE.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
